Differential receptor subunit affinities of type I interferons govern differential signal activation
- PMID: 17174979
- DOI: 10.1016/j.jmb.2006.11.053
Differential receptor subunit affinities of type I interferons govern differential signal activation
Abstract
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory responses by binding to a shared cell surface receptor comprising the transmembrane proteins ifnar1 and ifnar2. Activation of differential response patterns by IFNs has been observed, suggesting that members of the family play different roles in innate immunity. The molecular basis for differential signaling has not been identified yet. Here, we have investigated the recognition of various IFNs including several human IFNalpha species, human IFNomega and human IFNbeta as well as ovine IFNtau2 by the receptor subunits in detail. Binding to the extracellular domains of ifnar1 (ifnar1-EC) and ifnar2 (ifnar2-EC) was monitored in real time by reflectance interference and total internal reflection fluorescence spectroscopy. For all IFNs investigated, competitive 1:1 interaction not only with ifnar2-EC but also with ifnar1-EC was shown. Furthermore, ternary complex formation was studied with ifnar1-EC and ifnar2-EC tethered onto solid-supported membranes. These analyses confirmed that the signaling complexes recruited by IFNs have very similar architectures. However, differences in rate and affinity constants over several orders of magnitude were observed for both the interactions with ifnar1-EC and ifnar2-EC. These data were correlated with the potencies of ISGF3 activation, antiviral and anti-proliferative activity on 2fTGH cells. The ISGF3 formation and antiviral activity correlated very well with the binding affinity towards ifnar2. In contrast, the affinity towards ifnar1 played a key role for antiproliferative activity. A striking correlation was observed for relative binding affinities towards ifnar1 and ifnar2 with the differential antiproliferative potency. This correlation was confirmed by systematically engineering IFNalpha2 mutants with very high differential antiproliferative potency.
Similar articles
-
Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.J Mol Biol. 2004 Jul 30;341(1):303-18. doi: 10.1016/j.jmb.2004.05.059. J Mol Biol. 2004. PMID: 15312780
-
Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.J Mol Biol. 1999 Nov 19;294(1):223-37. doi: 10.1006/jmbi.1999.3230. J Mol Biol. 1999. PMID: 10556041
-
Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection.Biophys J. 2005 Jun;88(6):4289-302. doi: 10.1529/biophysj.104.055855. Epub 2005 Mar 18. Biophys J. 2005. PMID: 15778442 Free PMC article.
-
The Role of Structure in the Biology of Interferon Signaling.Front Immunol. 2020 Nov 12;11:606489. doi: 10.3389/fimmu.2020.606489. eCollection 2020. Front Immunol. 2020. PMID: 33281831 Free PMC article. Review.
-
Structure-function of type I and III interferons.Curr Opin Immunol. 2024 Feb;86:102413. doi: 10.1016/j.coi.2024.102413. Epub 2024 Apr 11. Curr Opin Immunol. 2024. PMID: 38608537 Free PMC article. Review.
Cited by
-
IFN-α subtypes: distinct biological activities in anti-viral therapy.Br J Pharmacol. 2013 Mar;168(5):1048-58. doi: 10.1111/bph.12010. Br J Pharmacol. 2013. PMID: 23072338 Free PMC article. Review.
-
Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice.Oncotarget. 2016 Nov 29;7(48):78412-78420. doi: 10.18632/oncotarget.12512. Oncotarget. 2016. PMID: 27729616 Free PMC article.
-
Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.J Interferon Cytokine Res. 2013 Apr;33(4):211-25. doi: 10.1089/jir.2012.0117. J Interferon Cytokine Res. 2013. PMID: 23570388 Free PMC article. Review.
-
Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.Immunol Rev. 2012 Nov;250(1):317-34. doi: 10.1111/imr.12001. Immunol Rev. 2012. PMID: 23046138 Free PMC article. Review.
-
Type I interferon-dependent CCL4 is induced by a cGAS/STING pathway that bypasses viral inhibition and protects infected tissue, independent of viral burden.PLoS Pathog. 2019 Oct 11;15(10):e1007778. doi: 10.1371/journal.ppat.1007778. eCollection 2019 Oct. PLoS Pathog. 2019. PMID: 31603920 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources